DK1352897T3 - Adamantanderivater til behandlingen af inflammatoriske sygdomme, immunsygdomme og cardiovaskulære sygdomme - Google Patents

Adamantanderivater til behandlingen af inflammatoriske sygdomme, immunsygdomme og cardiovaskulære sygdomme

Info

Publication number: DK1352897T3
Authority: DK; Denmark
Prior art keywords: immune; inflammatory; treatment; cardiovascular diseases; adamantan
Prior art date: 1999-12-17

Application number

DK03013991T

Other languages

English (en)

Inventor

Mark Furber

Paul Willis

Michael Mortimore

Lilian Alcaraz

Timothy Luker

Philip Thorne

Austen Pimm

Moya Caffrey

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-17

Filing date

2000-12-12

Publication date

2007-04-10

1999-12-17 Priority claimed from SE9904651A external-priority patent/SE9904651D0/xx

2000-06-27 Priority claimed from GB0015744A external-priority patent/GB0015744D0/en

2000-07-22 Priority claimed from GB0017942A external-priority patent/GB0017942D0/en

2000-12-12 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2007-04-10 Application granted granted Critical

2007-04-10 Publication of DK1352897T3 publication Critical patent/DK1352897T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)

DK03013991T 1999-12-17 2000-12-12 Adamantanderivater til behandlingen af inflammatoriske sygdomme, immunsygdomme og cardiovaskulære sygdomme DK1352897T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
SE9904651A SE9904651D0 (sv)	1999-12-17	1999-12-17	Novel compounds
GB0015744A GB0015744D0 (en)	2000-06-27	2000-06-27	Novel compounds
GB0017942A GB0017942D0 (en)	2000-07-22	2000-07-22	Novel compounds
PCT/SE2000/002505 WO2001044170A1 (en)	1999-12-17	2000-12-12	Adamantane derivatives

Publications (1)

Publication Number	Publication Date
DK1352897T3 true DK1352897T3 (da)	2007-04-10

Family

ID=27255782

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DK00986155T DK1242364T3 (da)	1999-12-17	2000-12-12	Adamantanderivater
DK03013991T DK1352897T3 (da)	1999-12-17	2000-12-12	Adamantanderivater til behandlingen af inflammatoriske sygdomme, immunsygdomme og cardiovaskulære sygdomme
DK03013989T DK1352895T3 (da)	1999-12-17	2000-12-12	Adamantanderivater til behandling af inflammatioriske immunologiske og kardiovaskulære sygdomme
DK03013990T DK1352896T3 (da)	1999-12-17	2000-12-12	Adamantanderivater til behandling af inflammations-, immun- og hjertekarsygdomme

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK00986155T DK1242364T3 (da)	1999-12-17	2000-12-12	Adamantanderivater

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK03013989T DK1352895T3 (da)	1999-12-17	2000-12-12	Adamantanderivater til behandling af inflammatioriske immunologiske og kardiovaskulære sygdomme
DK03013990T DK1352896T3 (da)	1999-12-17	2000-12-12	Adamantanderivater til behandling af inflammations-, immun- og hjertekarsygdomme

Country Status (32)

Country	Link
US (5)	US6881754B2 (da)
EP (5)	EP1352896B1 (da)
JP (2)	JP3710418B2 (da)
KR (2)	KR20070012883A (da)
CN (1)	CN1312120C (da)
AR (1)	AR035325A1 (da)
AT (4)	ATE376994T1 (da)
AU (2)	AU780506B2 (da)
BR (1)	BRPI0016395B8 (da)
CA (1)	CA2393352C (da)
CO (1)	CO5251381A1 (da)
CY (3)	CY1106357T1 (da)
CZ (1)	CZ20022093A3 (da)
DE (4)	DE60009147T2 (da)
DK (4)	DK1242364T3 (da)
EE (1)	EE05134B1 (da)
ES (4)	ES2279031T3 (da)
HK (1)	HK1046678B (da)
HU (1)	HUP0300616A3 (da)
IL (2)	IL150124A0 (da)
IS (1)	IS2246B (da)
MX (1)	MXPA02005789A (da)
MY (1)	MY125978A (da)
NO (1)	NO328682B1 (da)
NZ (1)	NZ519378A (da)
PL (1)	PL200836B1 (da)
PT (4)	PT1352895E (da)
SI (1)	SI1352895T1 (da)
SK (1)	SK286987B6 (da)
TR (1)	TR200401432T4 (da)
TW (1)	TWI258462B (da)
WO (1)	WO2001044170A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9904505D0 (sv)	1999-12-09	1999-12-09	Astra Pharma Prod	Novel compounds
TWI258462B (en)	1999-12-17	2006-07-21	Astrazeneca Ab	Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904738D0 (sv)	1999-12-22	1999-12-22	Astra Pharma Prod	Novel compounds
WO2003042190A1 (en)	2001-11-12	2003-05-22	Pfizer Products Inc.	N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (es)	2001-11-12	2003-06-30	Pfizer Prod Inc	Benzamida, heteroarilamida y amidas inversas
SE0200920D0 (sv) *	2002-03-25	2002-03-25	Astrazeneca Ab	Novel compounds
US7071223B1 (en) *	2002-12-31	2006-07-04	Pfizer, Inc.	Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es)	2002-12-31	2004-07-26	Pfizer Prod Inc	Inhibidores benzamidicos del receptor p2x7.
SE0300445D0 (sv) *	2003-02-18	2003-02-18	Astrazeneca Ab	New combination
SE0300480D0 (sv) *	2003-02-21	2003-02-21	Astrazeneca Ab	Novel compounds
ES2281801T3 (es) *	2003-05-12	2007-10-01	Pfizer Products Inc.	Inhibidores benzamida del receptor p2x7.
EP1644041A1 (en) *	2003-05-29	2006-04-12	AstraZeneca AB	A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
WO2004105796A1 (en) *	2003-05-29	2004-12-09	Astrazeneca Ab	A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
EP1633401A1 (en) *	2003-05-29	2006-03-15	AstraZeneca AB	A pharmaceutical composition comprising a p2x7-receptor antagonist and a tumour necrosis factor alpha
SE0302192D0 (sv) *	2003-08-08	2003-08-08	Astrazeneca Ab	Novel compounds
SE0302488D0 (sv) *	2003-09-18	2003-09-18	Astrazeneca Ab	New combination
CA2572119A1 (en) *	2004-06-29	2006-01-12	Warner-Lambert Company Llc	Combination therapies utilizing benzamide inhibitors of the p2x7 receptor
BRPI0512781A (pt) *	2004-06-29	2008-04-08	Pfizer Prod Inc	método para preparação de derivados de 5-{4-(2-hidroxi-propil)-3,5-dioxo-4,5-diidro-3h-[1,2,4]tria zin-2-il}-benzamida através da desproteção dos precursores de protetores de hidroxila
SA05260265A (ar) *	2004-08-30	2005-12-03	استرازينيكا ايه بي	مركبات جديدة
US20060063834A1 (en) *	2004-09-09	2006-03-23	Frangioni John V	Substituted adamantanes, and methods of making the same
SE0402925D0 (sv) *	2004-11-30	2004-11-30	Astrazeneca Ab	Novel Compounds
WO2007008155A1 (en) *	2005-07-11	2007-01-18	Astrazeneca Ab	New combination 1
WO2007008157A1 (en) *	2005-07-11	2007-01-18	Astrazeneca Ab	New combination 2
TW200819416A (en) *	2006-09-05	2008-05-01	Astrazeneca Ab	Novel process 470
KR101273200B1 (ko)	2008-02-06	2013-06-17	펄마젠 쎄라퓨틱스 (시너지) 리미티드	화합물
NZ587799A (en)	2008-03-25	2012-06-29	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
ES2380908T3 (es)	2009-04-14	2012-05-21	Affectis Pharmaceuticals Ag	Antagonistas de p2x7r novedosos y su uso
GB2469915A (en) *	2009-04-30	2010-11-03	Astrazeneca Ab	2-chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec- 1-ylmethyl)-benzamide hydrochloride salt
GB0913342D0 (en)	2009-07-31	2009-09-16	Astrazeneca Ab	Compounds - 801
EP2322149A1 (en)	2009-11-03	2011-05-18	Universidad del Pais Vasco	Methods and compositions for the treatment of ischemia
JP2013526496A (ja)	2010-05-14	2013-06-24	アフェクティスファーマシューティカルズアーゲー	Ｐ２ｘ７ｒ拮抗剤の新規調製方法
JP2013249256A (ja) *	2010-09-15	2013-12-12	Astellas Pharma Inc	脂肪性肝疾患治療薬
WO2012110190A1 (en)	2011-02-17	2012-08-23	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2012163792A1 (en)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2012163456A1 (en)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
KR101995088B1 (ko)	2011-07-22	2019-07-02	이도르시아 파마슈티컬스 리미티드	Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
NZ628910A (en)	2012-01-20	2016-02-26	Actelion Pharmaceuticals Ltd	Heterocyclic amide derivatives as p2x7 receptor antagonists
PL2931717T3 (pl)	2012-12-12	2017-05-31	Actelion Pharmaceuticals Ltd.	Pochodne indolokarboksyamidu jako antagoniści receptora p2x7
US9556117B2 (en)	2012-12-18	2017-01-31	Actelion Pharmaceuticals Ltd.	Indole carboxamide derivatives as P2X7 receptor antagonists
WO2014115078A1 (en)	2013-01-22	2014-07-31	Actelion Pharmaceuticals Ltd	Heterocyclic amide derivatives as p2x7 receptor antagonists
KR102222220B1 (ko)	2013-01-22	2021-03-03	이도르시아 파마슈티컬스 리미티드	Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
WO2023158601A2 (en) *	2022-02-15	2023-08-24	The Children's Medical Center Corporation	Compositions and methods relating to atp/p2x7r signaling inhibition
EP4230196A1 (en)	2022-02-21	2023-08-23	Som Innovation Biotech, S.A.	Compounds for use in the treatment of dystrophinopathies
WO2025024881A1 (en) *	2023-07-28	2025-02-06	The University Of Sydney	Adamantyl p2x7 receptor antagonists and their use in the treatment of cardiovascular diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3029241A (en)		1962-04-10		Phenylpbperazinylacyl anilines
US3464998A (en)	1968-03-04	1969-09-02	Searle & Co	Adamantyl esters and amides of pyridinecarboxylic acids
US3732305A (en)	1970-03-03	1973-05-08	Us Army	S-substituted thiosulfuric acid derivatives and preparation thereof
US3789072A (en)	1970-04-22	1974-01-29	Squibb & Sons Inc	Carboxamides
FR2346011A1 (fr)	1976-02-02	1977-10-28	Orsymonde	Acetanilido-piperazines
ZA825719B (en)	1981-09-03	1983-06-29	Recordati Chem Pharm	Alkanoylanilides
CA2015473C (en)	1989-04-28	1998-04-14	Iwao Kinoshita	Triphenylmethane derivatives
US6021024A (en) *	1992-02-21	2000-02-01	Kabushiki Kaisha Toshiba	Magnetic disk drive having a constant skew angle
CA2091194A1 (en)	1992-04-08	1993-10-09	Richard D. Connell	2-oxo-ethyl derivatives as immunosuppressants
ES2125285T3 (es)	1992-07-31	1999-03-01	Bristol Myers Squibb Co	Derivados inhibidores de la reabsorcion de adenosina de difenil-oxazoles, tiazoles e imidazoles.
PT720601E (pt)	1993-08-10	2001-02-28	Black James Foundation	Ligandos de receptores de gastrina e cck
US5530018A (en) *	1994-02-04	1996-06-25	G. D. Searle & Co.	Meso-azanoradamantanes
GB9409150D0 (en)	1994-05-09	1994-06-29	Black James Foundation	Cck and gastrin receptor ligands
WO1995032949A1 (en)	1994-05-27	1995-12-07	James Black Foundation Limited	Gastrin and cck antagonists
EP0786997A4 (en)	1994-10-27	1998-03-11	Merck & Co Inc	MUSCARINE ANTAGONISTS
DE19608653A1 (de)	1996-03-06	1997-09-11	Thomae Gmbh Dr K	Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
SE9704545D0 (sv)	1997-12-05	1997-12-05	Astra Pharma Prod	Novel compounds
SE9704544D0 (sv)	1997-12-05	1997-12-05	Astra Pharma Prod	Novel compounds
WO1999029640A2 (en) *	1997-12-05	1999-06-17	Eisai Co., Ltd.	Compositions and methods for modulating the activity of fibroblast growth factor
SE9704546D0 (sv)	1997-12-05	1997-12-05	Astra Pharma Prod	Novel compounds
US6018089A (en) *	1997-12-09	2000-01-25	Shell Oil Company	Process for separating linear internal olefins from branched internal olefins
AU1924099A (en)	1997-12-18	1999-07-05	Lyonnaise Industrielle Pharmaceutique (Lipha)	Piperazine derivatives useful as hypoglycemic agents
WO1999059582A1 (en)	1998-05-19	1999-11-25	Centaur Pharmaceuticals, Inc.	Amide therapeutics for the treatment of inflammatory bowel disease
HUP0202214A3 (en)	1999-04-09	2002-12-28	Astrazeneca Ab	Adamantane derivatives, preparation and use thereof
SE9901875D0 (sv)	1999-05-25	1999-05-25	Astra Pharma Prod	Novel compounds
SE9904505D0 (sv)	1999-12-09	1999-12-09	Astra Pharma Prod	Novel compounds
SE9904652D0 (sv)	1999-12-17	1999-12-17	Astra Pharma Prod	Novel Compounds
TWI258462B (en) *	1999-12-17	2006-07-21	Astrazeneca Ab	Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904738D0 (sv) *	1999-12-22	1999-12-22	Astra Pharma Prod	Novel compounds
GB0013737D0 (en)	2000-06-07	2000-07-26	Astrazeneca Ab	Novel compounds
US6555451B1 (en) *	2001-09-28	2003-04-29	The United States Of America As Represented By The Secretary Of The Navy	Method for making shallow diffusion junctions in semiconductors using elemental doping
SE0103836D0 (sv)	2001-11-16	2001-11-16	Astrazeneca Ab	Novel compounds
SE0200920D0 (sv)	2002-03-25	2002-03-25	Astrazeneca Ab	Novel compounds
SE0300480D0 (sv)	2003-02-21	2003-02-21	Astrazeneca Ab	Novel compounds
SE0302488D0 (sv)	2003-09-18	2003-09-18	Astrazeneca Ab	New combination
SA05260265A (ar)	2004-08-30	2005-12-03	استرازينيكا ايه بي	مركبات جديدة
SE0402925D0 (sv)	2004-11-30	2004-11-30	Astrazeneca Ab	Novel Compounds

2000
- 2000-12-04 TW TW089125761A patent/TWI258462B/zh not_active IP Right Cessation
- 2000-12-12 EP EP03013990A patent/EP1352896B1/en not_active Expired - Lifetime
- 2000-12-12 EP EP03013989A patent/EP1352895B1/en not_active Expired - Lifetime
- 2000-12-12 AT AT03013990T patent/ATE376994T1/de active
- 2000-12-12 DE DE60009147T patent/DE60009147T2/de not_active Expired - Lifetime
- 2000-12-12 AT AT03013991T patent/ATE350364T1/de active
- 2000-12-12 DE DE60032823T patent/DE60032823T2/de not_active Expired - Lifetime
- 2000-12-12 WO PCT/SE2000/002505 patent/WO2001044170A1/en not_active Ceased
- 2000-12-12 HK HK02108164.1A patent/HK1046678B/en not_active IP Right Cessation
- 2000-12-12 US US10/149,549 patent/US6881754B2/en not_active Expired - Lifetime
- 2000-12-12 BR BRPI0016395A patent/BRPI0016395B8/pt not_active IP Right Cessation
- 2000-12-12 MX MXPA02005789A patent/MXPA02005789A/es active IP Right Grant
- 2000-12-12 DK DK00986155T patent/DK1242364T3/da active
- 2000-12-12 ES ES03013991T patent/ES2279031T3/es not_active Expired - Lifetime
- 2000-12-12 AU AU22444/01A patent/AU780506B2/en not_active Expired
- 2000-12-12 PT PT03013989T patent/PT1352895E/pt unknown
- 2000-12-12 CO CO00094336A patent/CO5251381A1/es not_active Application Discontinuation
- 2000-12-12 DE DE60034155T patent/DE60034155T2/de not_active Expired - Lifetime
- 2000-12-12 PT PT03013991T patent/PT1352897E/pt unknown
- 2000-12-12 DK DK03013991T patent/DK1352897T3/da active
- 2000-12-12 EE EEP200200330A patent/EE05134B1/xx not_active IP Right Cessation
- 2000-12-12 DE DE60036968T patent/DE60036968T2/de not_active Expired - Lifetime
- 2000-12-12 AT AT03013989T patent/ATE358117T1/de active
- 2000-12-12 CA CA2393352A patent/CA2393352C/en not_active Expired - Lifetime
- 2000-12-12 JP JP2001545259A patent/JP3710418B2/ja not_active Expired - Lifetime
- 2000-12-12 ES ES03013989T patent/ES2282546T3/es not_active Expired - Lifetime
- 2000-12-12 ES ES00986155T patent/ES2215777T3/es not_active Expired - Lifetime
- 2000-12-12 SI SI200030950T patent/SI1352895T1/sl unknown
- 2000-12-12 IL IL15012400A patent/IL150124A0/xx not_active IP Right Cessation
- 2000-12-12 PT PT00986155T patent/PT1242364E/pt unknown
- 2000-12-12 DK DK03013989T patent/DK1352895T3/da active
- 2000-12-12 KR KR1020077000596A patent/KR20070012883A/ko not_active Ceased
- 2000-12-12 ES ES03013990T patent/ES2294219T3/es not_active Expired - Lifetime
- 2000-12-12 CZ CZ20022093A patent/CZ20022093A3/cs unknown
- 2000-12-12 NZ NZ519378A patent/NZ519378A/en not_active IP Right Cessation
- 2000-12-12 PL PL355913A patent/PL200836B1/pl not_active IP Right Cessation
- 2000-12-12 EP EP07014968A patent/EP1862451A1/en not_active Withdrawn
- 2000-12-12 PT PT03013990T patent/PT1352896E/pt unknown
- 2000-12-12 EP EP00986155A patent/EP1242364B1/en not_active Expired - Lifetime
- 2000-12-12 TR TR2004/01432T patent/TR200401432T4/xx unknown
- 2000-12-12 CN CNB008189226A patent/CN1312120C/zh not_active Expired - Lifetime
- 2000-12-12 KR KR1020027007702A patent/KR100710110B1/ko not_active Expired - Lifetime
- 2000-12-12 SK SK841-2002A patent/SK286987B6/sk not_active IP Right Cessation
- 2000-12-12 AT AT00986155T patent/ATE261933T1/de active
- 2000-12-12 EP EP03013991A patent/EP1352897B1/en not_active Expired - Lifetime
- 2000-12-12 HU HU0300616A patent/HUP0300616A3/hu unknown
- 2000-12-12 DK DK03013990T patent/DK1352896T3/da active
- 2000-12-15 AR ARP000106695A patent/AR035325A1/es active IP Right Grant
- 2000-12-15 MY MYPI20005926A patent/MY125978A/en unknown
2002
- 2002-05-31 IS IS6406A patent/IS2246B/is unknown
- 2002-06-14 NO NO20022856A patent/NO328682B1/no not_active IP Right Cessation
2004
- 2004-03-31 US US10/813,426 patent/US7132457B2/en not_active Expired - Lifetime
2005
- 2005-05-27 AU AU2005202321A patent/AU2005202321B2/en not_active Ceased
- 2005-06-03 JP JP2005163710A patent/JP2005320340A/ja active Pending
2006
- 2006-09-29 US US11/529,746 patent/US7297818B2/en not_active Expired - Fee Related
2007
- 2007-03-06 CY CY20071100312T patent/CY1106357T1/el unknown
- 2007-05-17 CY CY20071100671T patent/CY1106602T1/el unknown
- 2007-06-20 US US11/812,673 patent/US20080139636A1/en not_active Abandoned
- 2007-12-19 CY CY20071101609T patent/CY1107838T1/el unknown
2008
- 2008-02-25 IL IL189758A patent/IL189758A0/en not_active IP Right Cessation
- 2008-12-04 US US12/314,156 patent/US20090176853A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN1434794A (zh)	2003-08-06
ATE358117T1 (de)	2007-04-15
EP1352895B1 (en)	2007-03-28
DK1352896T3 (da)	2008-01-28
PT1352896E (pt)	2007-12-19
CZ20022093A3 (cs)	2003-01-15
CA2393352C (en)	2011-08-30
EP1352896A3 (en)	2003-12-03
NO20022856D0 (no)	2002-06-14
NO20022856L (no)	2002-08-16
AU2244401A (en)	2001-06-25
CY1106357T1 (el)	2011-10-12
TWI258462B (en)	2006-07-21
EP1242364B1 (en)	2004-03-17
CA2393352A1 (en)	2001-06-21
KR20020061646A (ko)	2002-07-24
PT1242364E (pt)	2004-07-30
US7297818B2 (en)	2007-11-20
WO2001044170A1 (en)	2001-06-21
US20050049303A1 (en)	2005-03-03
US20030013704A1 (en)	2003-01-16
PL355913A1 (en)	2004-05-31
MXPA02005789A (es)	2002-09-18
JP3710418B2 (ja)	2005-10-26
NO328682B1 (no)	2010-04-26
ES2282546T3 (es)	2007-10-16
KR100710110B1 (ko)	2007-04-20
IS6406A (is)	2002-05-31
US7132457B2 (en)	2006-11-07
ES2294219T3 (es)	2008-04-01
HK1057035A1 (en)	2004-03-12
BR0016395B1 (pt)	2013-10-08
AR035325A1 (es)	2004-05-12
MY125978A (en)	2006-09-29
DK1352895T3 (da)	2007-06-11
DE60032823T2 (de)	2007-11-08
EP1862451A1 (en)	2007-12-05
EP1352895A3 (en)	2003-12-03
HK1046678B (en)	2004-12-03
DE60034155T2 (de)	2007-12-13
CY1107838T1 (el)	2013-06-19
US20090176853A1 (en)	2009-07-09
ATE350364T1 (de)	2007-01-15
NZ519378A (en)	2004-02-27
US6881754B2 (en)	2005-04-19
EP1242364A1 (en)	2002-09-25
PT1352895E (pt)	2007-05-31
US20070082957A1 (en)	2007-04-12
DE60036968T2 (de)	2008-08-14
CN1312120C (zh)	2007-04-25
PL200836B1 (pl)	2009-02-27
ATE376994T1 (de)	2007-11-15
HK1046678A1 (en)	2003-01-24
CY1106602T1 (el)	2012-01-25
EP1352897A2 (en)	2003-10-15
HUP0300616A3 (en)	2004-08-30
JP2005320340A (ja)	2005-11-17
JP2003517035A (ja)	2003-05-20
HUP0300616A2 (hu)	2003-07-28
US20080139636A1 (en)	2008-06-12
BR0016395A (pt)	2002-08-27
ATE261933T1 (de)	2004-04-15
ES2279031T3 (es)	2007-08-16
IL150124A0 (en)	2002-12-01
TR200401432T4 (tr)	2004-08-23
IS2246B (is)	2007-06-15
IL189758A0 (en)	2008-06-05
DE60032823D1 (de)	2007-02-15
EP1352897A3 (en)	2003-12-03
EP1352896B1 (en)	2007-10-31
BRPI0016395B8 (pt)	2021-05-25
EP1352896A2 (en)	2003-10-15
SI1352895T1 (sl)	2007-08-31
SK8412002A3 (en)	2003-02-04
CO5251381A1 (es)	2003-02-28
EE200200330A (et)	2003-10-15
EP1352895A2 (en)	2003-10-15
DE60009147T2 (de)	2005-04-21
AU780506B2 (en)	2005-03-24
DE60034155D1 (de)	2007-05-10
EP1352897B1 (en)	2007-01-03
EE05134B1 (et)	2009-02-16
DK1242364T3 (da)	2004-06-21
SK286987B6 (sk)	2009-08-06
AU2005202321B2 (en)	2008-05-22
AU2005202321A1 (en)	2005-06-23
KR20070012883A (ko)	2007-01-29
DE60009147D1 (de)	2004-04-22
DE60036968D1 (de)	2007-12-13
PT1352897E (pt)	2007-03-30
ES2215777T3 (es)	2004-10-16

Publication	Publication Date	Title
DK1352896T3 (da)	2008-01-28	Adamantanderivater til behandling af inflammations-, immun- og hjertekarsygdomme
DK1143977T3 (da)	2005-08-15	2-oxy-benzoxazinonderivater til behandling af obesitas
DK1459750T3 (da)	2005-08-15	(S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser
NO20041216L (no)	2004-05-05	Imidazol-4-karboksamidderivater, fremstilling og anvendelse derav for behandling av overvekt
NO20051493L (no)	2005-03-21	Imidazolpyridiner og fremgangsmater for fremstilling og anvendelse av de samme
DK0971735T3 (da)	2008-07-07	Fremgangsmåder og præparater til behandling af inflammatorisk tarmsygdom
IS7684A (is)	2005-02-03	Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
IS7202A (is)	2004-03-31	Samsetningar til meðhöndlunar á ónæmisbólgusjúkdómum
NO20051503D0 (no)	2005-03-21	Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
DK199900790A (da)	2000-12-05	Fremgangsmåde og anlæg til behandling af mælk
NO20015542L (no)	2002-01-14	Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
DK1150991T3 (da)	2004-06-07	Præparater til behandling af inflammatoriske reaktioner
IS6077A (is)	2001-09-18	Efnasambönd og aðferðir til meðhöndlunar á asma, ofnæmi og bólgutruflunum
NO20015772L (no)	2002-01-22	Forbindelser og fremgangsmåter for behandling av post- traumatisk stress-syndrom
IS7275A (is)	2004-05-21	Samsetning fyrir hollegg og notkun á henni
NO20010464D0 (no)	2001-01-26	Fremgangsmåter og sammensetninger for behandling av gastroösofrageal-reflukssyndrom
IS3004B (is)	2018-09-15	Aðferð til meðhöndlunar á svefnleysi á frumstigi
DK1200114T3 (da)	2009-08-03	PPAR delta inhibitorer til behandling af kardiovaskulære sygdomme
DK1229906T3 (da)	2008-02-11	Mesoprogestiner til behandlingen og forebyggelsen af godartede, hormonafhængige, gynækologiske lidelser
NO20023737D0 (no)	2002-08-07	Fremgangsmåte og preparater for behandling av en inflammatorisk lidelse
IS6707A (is)	2003-02-03	Efnablanda til forvarna og meðhöndlunar á krabbameini
DK1341758T3 (da)	2006-10-30	Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme
DK1200447T3 (da)	2004-02-02	Oxazinocarbazoler til behandling af CNS-sygdomme
IS6098A (is)	2001-09-28	Ósantant til meðhöndlunar á skaptruflunum
DK1493442T3 (da)	2005-12-19	Reboxetin til behandling af perifer neuropati